Ethambutol

Q: To which line of antitubercular drugs (first or second) does ethambutol belong?

Ethambutol (Ethambutolum) is a first-line antitubercular agent (a primary drug of choice for treating tuberculosis caused by susceptible mycobacteria).

Q: What adverse effects does ethambutol cause?

Retrobulbar neuritis is the key toxic effect, manifesting as decreased visual acuity, scotomas, visual field constriction, pain on eye movement, and impaired color vision (loss of sensitivity to the red-green spectrum).

Q: What are the absolute contraindications to prescribing ethambutol?

Eye disorders (morbi oculorum)—ocular pathologies accompanied by decreased visual acuity are direct contraindications to prescribing ethambutol per product labeling.

Q: Is dose adjustment of ethambutol required in renal impairment?

Dose adjustment (correctio dosas) is required; the drug belongs to the group of antitubercular agents requiring dosage modification or altered dosing intervals.

*Ethambutolum*

For medical students2 min readUpdated 2026-10-10

Ethambutol is a highly effective synthetic antitubercular agent and an ethylenediamine derivative. The drug specifically disrupts the mycobacterial cell wall by blocking specific enzymatic systems, making it a vital component of modern combination regimens.

Chemical natureSynthetic ethylenediamine derivative

Primary targetArabinosyltransferase enzyme

ToxicityRetrobulbar neuritis (loss of red-green color vision)

Route of administrationOrally, strictly in combination therapy

Chemical Nature and Resistance Profile

In pharmacological classification, ethambutol belongs to synthetic antibacterial agents. Chemically, the drug molecule is an ethylenediamine derivative. When examining the structural formulas of antitubercular drugs, it is often grouped alongside thioamides, such as ethionamide and prothionamide. However, its ethylenediamine structure confers its unique properties.

A key clinical advantage of ethambutol is its ability to overcome drug resistance. Cross-resistance, where bacteria stop responding to related drugs, is a major therapeutic challenge. Due to its entirely unique mechanism of action, ethambutol maintains high therapeutic activity against mycobacterial strains that have already developed resistance to classical agents such as streptomycin and isoniazid.

Mechanism of Action: Disrupting the Cell Wall

The action of ethambutol on mycobacteria is highly selective. The drug does not merely destroy the cell; it disrupts its natural synthesis process. This process involves several key steps:

Target binding: Upon penetrating the infection site, the ethambutol molecule targets its primary receptor—the specific bacterial enzyme arabinosyltransferase.
Blockade: By binding to the enzyme, the drug heavily interferes with the biochemical reactions of arabinogalactan synthesis.
Localized effect: Arabinogalactan is a crucial structural component. Its deficiency impairs the correct assembly of the mycobacterial cell wall.

As a result of this pharmacological intervention, the bacterium loses its rigid outer envelope, making further replication and survival impossible.

Pharmacokinetics: Absorption to Elimination

Ethambutol features a favorable pharmacokinetic profile that ensures high efficacy in systemic treatment. Its pathway in the body is as follows:

Absorption: The drug is administered orally. After entering the gastrointestinal tract (GIT), it demonstrates a very high degree of systemic absorption.
Distribution: Ethambutol molecules are widely distributed, penetrating most tissues and body fluids. Of particular clinical importance is the drug's ability to successfully cross the blood-brain barrier (BBB).
Elimination: After completing its pharmacological task, the drug is eliminated. The primary route of elimination for ethambutol is renal excretion.

Clinical Application and Toxicity

In clinical practice, ethambutol is administered strictly via the oral route. A cardinal rule of modern pharmacotherapy is the prohibition of monotherapy. Ethambutol is used solely as part of combination therapy, most commonly prescribed alongside potent agents such as rifampin or isoniazid.

Despite its high efficacy, ethambutol use is strictly limited by its adverse effects. The key toxicity profile of the drug that every physician must keep in mind is retrobulbar neuritis. This specific optic nerve damage presents with clear clinical manifestations:

Progressive decrease in patient visual acuity.
Impaired color vision, predominantly affecting the red-green color spectrum (patients lose the ability to adequately distinguish red and green colors).

Mnemonic

To remember ethambutol toxicity, use the traffic light mnemonic: ETHAMBUTOL turns off the RED and GREEN lights (loss of red-green color discrimination due to retrobulbar neuritis).

Frequently asked questions

To which line of antitubercular drugs (first or second) does ethambutol belong?

Ethambutol (Ethambutolum) is a first-line antitubercular agent (a primary drug of choice for treating tuberculosis caused by susceptible mycobacteria).

What adverse effects does ethambutol cause?

Retrobulbar neuritis is the key toxic effect, manifesting as decreased visual acuity, scotomas, visual field constriction, pain on eye movement, and impaired color vision (loss of sensitivity to the red-green spectrum).

What are the absolute contraindications to prescribing ethambutol?

Eye disorders (morbi oculorum)—ocular pathologies accompanied by decreased visual acuity are direct contraindications to prescribing ethambutol per product labeling.

Is dose adjustment of ethambutol required in renal impairment?

Dose adjustment (correctio dosas) is required; the drug belongs to the group of antitubercular agents requiring dosage modification or altered dosing intervals.

Why does ethambutol remain effective against strains resistant to isoniazid and streptomycin?

The secret lies in the absence of cross-resistance. Ethambutol has a unique mechanism of action—it selectively blocks the enzyme arabinosyltransferase, whereas isoniazid and streptomycin act on completely different targets.

What are the distribution characteristics of ethambutol following oral administration?

Following high gastrointestinal absorption, the drug demonstrates very wide distribution. It penetrates most tissues and fluids, and is capable of crossing the blood-brain barrier (BBB).

Is it appropriate to use ethambutol as a single agent for treatment?

Categorically no. Per treatment guidelines, ethambutol must be administered exclusively as part of combination therapy (e.g., alongside rifampin or isoniazid).

Which specific adverse effect requires visual monitoring?

The main toxic effect of ethambutol is retrobulbar neuritis, manifested by decreased visual acuity and characteristic color vision impairment (loss of sensitivity to the red-green spectrum).

Go deeper

Detailed analysis of chemical structure: differences between ethylenediamine derivatives and thioamides (ethionamide and prothionamide).
Biochemical role of arabinosyltransferase in the synthesis of cell wall arabinogalactan.
Pharmacokinetics of antitubercular agents: mechanisms of crossing the blood-brain barrier (BBB).
Principles of combination therapy design: synergy of ethambutol with rifampin and isoniazid.
Pathogenesis and clinical presentation of retrobulbar neuritis during prolonged ethambutol therapy.